丙肝医学知识更新8月份三亚教学文稿.pptx

2016 丙肝医学知识更新医学部 徐颖颖 李润琴 魏岚2016.08.02 三亚仅限内部培训使用主要内容BMS 丙肝研发历程AI 447-036 study HCV Soc surveyCCgenos study 中国丙肝研究数据HCV 常见问题BMS丙肝研发里程碑事件NS5ANS5BNS34B201220132014+198920102011DAA = direct-acting antiviral; PegIFN = pegylated interferon; DCV = daclatasvir; ASV = asunaprevir; RBV = ribavirin; SOV = sofosbuvir; SVR12 = sustained virologic response 12 weeks post-treatment; SVR24 = sustained virologic response 24 weeks post-treatment; SVR4 = sustained virologic response 4 weeks post-treatment.1. Choo Ql, et al. Science. 1989;244(4902):359-362.2. Tellinghuisen TL, et al. Nature. 2005;435(7040):374-379.4. Freeman JA, et al. Hepatology. 2010 52 SUPPL.1 (721A). First to target NS5A1,2Non-structural protein 5AEssential for HCV viral replicationModulates virion morphogenesisDiscovery of daclatasvir: potent small molecule NS5A inhibitor3BMS丙肝研发里程碑事件Potent, specific NS5A inhibitorInhibits multiple stages of viral RNA replicationPangenotypic efficacy2014+20122013198920102011DAA = direct-acting antiviral; PegIFN = pegylated interferon; DCV = daclatasvir; ASV = asunaprevir; RBV = ribavirin; SOV = sofosbuvir; SVR12 = sustained virologic response 12 weeks post-treatment; SVR24 = sustained virologic response 24 weeks post-treatment; SVR4 = sustained virologic response 4 weeks post-treatment.3. Gao M, et al. Nature. 2010;465(7294):96-100.BMS丙肝研发里程碑事件First to demonstrate that dual DAAs can enhance the efficacy of PegIFN/RBV regimen4Adding daclatasvir + asunaprevir (NS3/4 protease inhibitor) to PegIFN/RBV improved SVR24GT 1 null responders 2014+DAA = direct-acting antiviral; PegIFN = pegylated interferon; DCV = daclatasvir; ASV = asunaprevir; RBV = ribavirin; SOV = sofosbuvir; SVR12 = sustained virologic response 12 weeks post-treatment; SVR24 = sustained virologic response 24 weeks post-treatment; SVR4 = sustained virologic response 4 weeks post-treatment.1. Choo Ql, et al. Science. 1989;244(4902):359-362.2. Tellinghuisen TL, et al. Nature. 2005;435(7040):374-379.3. Gao M, et al. Nature.